ArticleCancers2019

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Fatih M Uckun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.